Small cap ASX healthcare stocks potentially tipped for growth

The following ASX small cap healthcare stocks are supported by long-term industry tailwinds and offer substantial upside potential for investors because of key clinical, regulatory and commercial milestones.

ASX Small cap healthcare stocks

Actinogen Medical Limited (ASX: ACW)

Prescient Therapeutics Limited (ASX: PTX)

Botanix Pharmaceuticals Limited (ASX: BOT)

Actinogen Medical Limited (ASX: ACW)

on 18 December announced that enrolment in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial has been fully completed as the 246th and final participant has now been randomised and dosed which confirms that topline results remain on schedule for release in November 2026.

The company received $5.5 million from the first tranche of its FY25 R&D tax incentive and expects a further $1.9 million rebate which lifts the pro forma cash position to approximately $12.4 million.
The company is moving into a data focused phase with an interim analysis planned for January 2026 as the independent Data Monitoring Committee reviews unblinded data from completed patient visits.

From an investment standpoint, ACW provides leveraged exposure to a differentiated oral Alzheimer’s therapy at an advanced clinical stage supported by multiple near-term catalysts that could impact investor sentiment.

Prescient Therapeutics Limited (ASX: PTX)

announced on 15 December that it has received authorisation from the European Clinical Trials Information System to begin its PTX-100 clinical study in Italy for patients with relapsed or refractory cutaneous T-cell lymphoma.
This approval enables the company to activate clinical trial sites and start enrolling patients for the Phase 2a study across several European countries.

During the September quarter, Prescient completed a $9.8 million capital raising and ended the quarter with cash reserves of $12.32 million.

The proceeds from the placement are being used to advance the global Phase 2 clinical program for PTX-100 in cutaneous T-cell lymphoma.

For investors who are aiming for significant upside driven by progress in clinical development, Prescient Therapeutics represents a good opportunity at its current stage of growth.

Botanix Pharmaceuticals Limited (ASX: BOT)

recorded a strong start to FY26 as recent developments point to rising commercial traction for Sofdra as total prescriptions shipped increased 50% quarter-on-quarter to 20,418 while unaudited net revenue rose 65% to $7.1 million in the September 2025 quarter.

Operating cash outflow improved as it declined from $28.4 million in Q4 FY25 to $13.1 million in Q1 FY26 supported by a solid balance sheet with a cash position of $49.2 million as at 30 September 2025.
The company expects sales momentum to continue through FY26 with Sofdra uptake to accelerate further in the December and March quarters as the expanded sales team reaches full productivity.

With an FDA approved first in class product, growing recurring revenue, improving cash flow dynamics and a clear pathway to profitability, Botanix is well positioned to deliver sustained revenue growth and long-term value creation.

(Source: Company Reports)